Sustained Clinical Response to 4th-Line Therapy with Selpercatinib in RET Fusion-Positive Combined Small Cell Lung Cancer

References

• WHO Classification of Tumours Editorial Board. Thoracic Tumours. 5th ed. Lyon, France: International Agency for Research on Cancer; 2021.
   Google Scholar
• Nicholson SA, Beasley MB, Brambilla E, et al. Small cell lung carcinoma (SCLC): a clinicopathologic study of 100 cases with surgical specimens. Am J Surg Pathol. 2002;26(9):1184–1197. doi:10.1097/00000478-200209000-00009
   PubMed Web of Science ®Google Scholar
• Qin J, Lu H. Combined small-cell lung carcinoma. Onco Targets Ther. 2018;19(11):3505–3511. doi:10.2147/OTT.S159057
   Google Scholar
• National Comprehensive Cancer Network. Small Cell Lung Cancer (version 3.2023). Available from: https://www.nccn.org/professionals/physician_gls/pdf/sclc.pdf. Accessed November 27, 2023.
   Google Scholar
• Kohno T, Tsuta K, Tsuchihara K, et al. RET fusion gene: translation to personalized lung cancer therapy. Cancer Sci. 2013;104(11):1396–1400. doi:10.1111/cas.12275
   PubMed Web of Science ®Google Scholar
• Subbiah V, Cote GJ. Advances in Targeting RET-Dependent Cancers. Cancer Discov. 2020;10(4):498–505. doi:10.1158/2159-8290.CD-19-1116
   PubMed Web of Science ®Google Scholar
• Drusbosky LM, Rodriguez E, Dawar R, et al. Therapeutic strategies in RET gene rearranged non-small cell lung cancer. J Hematol Oncol. 2021;14(1):50. doi:10.1186/s13045-021-01063-9
   PubMed Web of Science ®Google Scholar
• Wang R, Hu H, Pan Y, et al. RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer. J Clin Oncol. 2012;30(35):4352–4359. doi:10.1200/JCO.2012.44.1477
   PubMed Web of Science ®Google Scholar
• Drilon A, Lin JJ, Filleron T, et al. Frequency of brain metastases and multikinase inhibitor outcomes in patients with RET-rearranged lung cancers. J Thorac Oncol. 2018;13(10):1595–1601. doi:10.1016/j.jtho.2018.07.004
   PubMed Web of Science ®Google Scholar
• Shi M, Wang W, Zhang J, et al. Identification of RET fusions in a Chinese multicancer retrospective analysis by next-generation sequencing. Cancer Sci. 2022;113(1):308–318. doi:10.1111/cas.15181
   PubMed Web of Science ®Google Scholar
• Ignatius Ou S-H, Zhu VW. Catalog of 5’ fusion partners in RET+ NSCLC Circa 2020. JTO Clin Res Rep. 2020;1(2):100037. doi:10.1016/j.jtocrr.2020.100037
   PubMedGoogle Scholar
• Feng J, Li Y, Wei B, et al. Clinicopathologic characteristics and diagnostic methods of RET rearrangement in Chinese non-small cell lung cancer patients. Transl Lung Cancer Res. 2022;11(4):617–631. doi:10.21037/tlcr-22-202
   PubMed Web of Science ®Google Scholar
• Larkin HD. Selpercatinib receives regular approval for non-small cell lung cancer. JAMA. 2022;328(17):1679. doi:10.1001/jama.2022.18445
   Web of Science ®Google Scholar
• Markham A. Pralsetinib: first Approval. Drugs. 2020;80(17):1865–1870. doi:10.1007/s40265-020-01427-4
   PubMed Web of Science ®Google Scholar
• Novello S, Califano R, Reinmuth N, et al. RET fusion-positive non-small cell lung cancer: the evolving treatment landscape. Oncologist. 2023;28(5):402–413. doi:10.1093/oncolo/oyac264
   PubMed Web of Science ®Google Scholar
• Li Y, Chen R, Yuan M, et al. One-stop molecular classification of endometrial carcinoma using comprehensive next-generation sequencing. Int J Cancer. 2022;151(11):1969–1977. doi:10.1002/ijc.34241
   PubMed Web of Science ®Google Scholar
• Zhao X, McCutcheon JN, Kallakury B, et al. Combined small cell carcinoma of the lung: is it a single entity? J Thorac Oncol. 2018;13(2):237–245. doi:10.1016/j.jtho.2017.10.010
   PubMed Web of Science ®Google Scholar
• Zhang J, Zhang L, Luo J, et al. Comprehensive genomic profiling of combined small cell lung cancer. Transl Lung Cancer Res. 2021;10(2):636–650. doi:10.21037/tlcr-20-1099
   PubMed Web of Science ®Google Scholar
• Simbolo M, Centonze G, Ali G, et al. Integrative molecular analysis of combined small-cell lung carcinomas identifies major subtypes with different therapeutic opportunities. ESMO Open. 2022;7(1):100308. doi:10.1016/j.esmoop.2021.100308
   PubMed Web of Science ®Google Scholar
• Niitsu T, Shiroyama T, Miyake K, et al. Combined small cell lung carcinoma harboring ALK rearrangement: a case report and literature review. Thorac Cancer. 2020;11(12):3625–3630. doi:10.1111/1759-7714.13716
   PubMed Web of Science ®Google Scholar
• Lu H, Xu H, Xie F, et al. 1p/19q codeletion and RET rearrangements in small-cell lung cancer. Onco Targets Ther. 2016;16(9):3571–3577. doi:10.2147/OTT.S108781
   Google Scholar
• Mulligan LM, Timmer T, Ivanchuk SM, et al. Investigation of the genes for RET and its ligand complex, GDNF/GFR alpha-I, in small cell lung carcinoma. Genes Chromos Cancer. 1998;21(4):326–332. doi:10.1002/(SICI)1098-2264(199804)21:4<326::AID-GCC6>3.0.CO;2-0
   PubMed Web of Science ®Google Scholar
• Lou G, Yu X, Song Z. Molecular profiling and survival of completely resected primary pulmonary neuroendocrine carcinoma. Clin Lung Cancer. 2017;18(3):e197–e201. doi:10.1016/j.cllc.2016.11.014
   PubMed Web of Science ®Google Scholar
• Arora A, Zaemes J, Ozdemirli M, et al. Response to selpercatinib in a patient with RET fusion-positive pulmonary large-cell neuroendocrine carcinoma: a case report. Front Oncol. 2023;13:1134151. doi:10.3389/fonc.2023.1134151
   PubMed Web of Science ®Google Scholar
• Lei L, Chen Q, Wang Z, et al. Usefulness of carcinoembryonic antigen in the diagnosis of small cell lung cancer combined with adenocarcinoma. Adv Clin Exp Med. 2017;26(7):1091–1094. doi:10.17219/acem/66372
   PubMed Web of Science ®Google Scholar
• Subbiah V, Gainor JF, Oxnard GR, et al. Intracranial efficacy of selpercatinib in ret fusion-positive non-small cell lung cancers on the LIBRETTO-001 trial. Clin Cancer Res. 2021;27(15):4160–4167. doi:10.1158/1078-0432.CCR-21-0800
   PubMed Web of Science ®Google Scholar
• Drilon A, Subbiah V, Gautschi O, et al. Selpercatinib in patients with RET fusion-positive non-small-cell lung cancer: updated safety and efficacy from the registrational LIBRETTO-001 phase I/II trial. J Clin Oncol. 2023;41(2):385–394. doi:10.1200/JCO.22.00393
   PubMed Web of Science ®Google Scholar
• Illini O, Hochmair MJ, Fabikan H, et al. Selpercatinib in RET fusion-positive non-small-cell lung cancer (SIREN): a retrospective analysis of patients treated through an access program. Ther Adv Med Oncol. 2021;11(13):17588359211019675. doi:10.1177/17588359211019675
   Google Scholar
• Babakoohi S, Fu P, Yang M, et al. Combined SCLC clinical and pathologic characteristics. Clin Lung Cancer. 2013;14(2):113–119. doi:10.1016/j.cllc.2012.07.002
   PubMed Web of Science ®Google Scholar
• Yang L, Zhou Y, Wang G, et al. Clinical features and prognostic factors of combined small cell lung cancer: development and validation of a nomogram based on the SEER database. Transl Lung Cancer Res. 2021;10(11):4250–4265. doi:10.21037/tlcr-21-804
   PubMed Web of Science ®Google Scholar